XJPX
9776
Market cap40mUSD
Feb 13, Last price
1,952.00JPY
Name
Sapporo Clinical Laboratory Inc
Chart & Performance
P/E
14.01
P/S
0.32
EPS
139.37
Div Yield, %
1.18%
Shrs. gr., 5y
-1.78%
Rev. gr., 5y
2.66%
Revenues
20.13b
+2.28%
Net income
464m
+22.10%
CFO
731m
-32.17%
Dividend
Mar 30, 202623 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Sapporo, Japan in 1965, Sapporo Clinical Laboratory Inc. operates a network of dispensing pharmacies across the country. The company provides an extensive array of diagnostic services, including clinical, pathological, and Holter examinations. Its services also extend to environmental health, offering food hygiene assessments that cover processed products, facility cleanliness, and food handler practices, as well as radiation safety management. Furthermore, Sapporo Clinical Laboratory Inc. develops, markets, and maintains specialized software, such as SCAN clinical testing systems. It also delivers support for establishing new clinics and offers the HiWeb21 platform for accessing inspection results. Additionally, the company provides ongoing sales and maintenance for a variety of clinical testing software solutions.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||